目的:觀察白芍總苷(TGP)聯合甲氨喋呤(MTX)和柳氮磺吡啶(SASP)治療強直性脊柱炎(AS)療效和安全性。方法:58例符合強直性脊柱炎標準的患者隨機納入2組:治療組:29例,口服白芍總苷+甲氨喋呤+柳氮磺吡啶;對照組:29例,口服甲氨喋呤+柳氮磺吡啶,兩組療程均為3月。結果:經3月治療,兩組間Schober實驗、胸廓擴張度、晨僵持續時間、血沉(ESR)及C反應蛋白(CRP)等5項指標較治療前均顯著降低(Plt;0.01),但治療組上述指標改善值優于對照組,差異分別有顯著意義(Plt;0.05)或極顯著意義(Plt;0.01);治療組不良反應發生率明顯少于對照組(Plt;0.05)。結論:白芍總苷聯合甲氨喋呤和柳氮磺吡啶是治療強直性脊柱炎安全有效方法。
Sepsis-associated organ dysfunction arises from uncontrolled inflammation and immune dysregulation, causing microcirculatory impairment and multi-organ failure. Stellate ganglion block (SGB) may confer organ protection by regulating the sympathetic nervous system and hypothalamic-pituitary-adrenal axis to suppress excessive inflammation and oxidative stress. Available evidence, mainly from experimental and small clinical studies, suggests potential benefits of SGB in sepsis-induced acute lung injury, ventricular arrhythmias, and limb ischemia, which require confirmation in multicenter randomized controlled trials. This review outlines the mechanisms and clinical advances of SGB in sepsis-related organ dysfunction, providing a theoretical basis for its application in critical care.